Skip to content

Women's Treatment and Early Recovery

Neural Mechanisms in Women's Treatment and Early Recovery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02977988
Acronym
MBRP-W
Enrollment
200
Registered
2016-11-30
Start date
2015-10-15
Completion date
2019-06-30
Last updated
2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance-related Disorders

Keywords

Mindfulness, Women, Relapse prevention, Clinical trial, Substance use disorder, Ethnically diverse, Underserved, Health disparities, Stress, Addiction, Latina/Hispanic, African American, Treatment retention, Residential treatment, Brain Imaging

Brief summary

Approximately 25 million Americans struggle with alcohol or drug problems annually. Abuse of alcohol and drugs is costly to our nation, exacting more than $428 billion in costs related to crime, lost work productivity and health care. While effective treatments exist, over half of those who enter treatment for substance use disorders drop out early in treatment and return to alcohol or drug abuse. Psychological stress is a causal factor in the pathogenesis of substance use disorder (SUD) and relapse risk. Low-income women report high levels of stress in SUD residential treatment stemming from significant economic and family stressors in addition to challenges of adjusting to residential treatment demands. Unmanaged stress, especially in early stages of residential treatment, is a major concern because it can increase dropout. Dropout from residential treatment places women at risk of substance use relapse. A gap in knowledge persists regarding the use of mindfulness-based interventions with racially/ethnically diverse low-income women with SUDs, especially regarding the efficacy of adapted (Mindfulness-based interventions) MBIs for preventing residential dropout and decreasing relapse. We have fully adapted, developed, and pilot tested a novel MBI, Moment-by-Moment in Women's Recovery: Mindfulness Based Relapse Prevention for Women (MBRP-W), that supports the needs of women in residential treatment. This MBI integrates relapse prevention, addresses literacy level, and is relevant to issues surrounding treatment- and relapse-related stressors of disadvantaged women. The current project has three specific aims: (1) to test the efficacy of MBRP-W on residential treatment retention and substance use relapse in racially/ethnically diverse low-income women; (2) to determine the mechanisms of change underlying the MBRP-W program; and (3) to explore neural changes associated with program effects. A rationale for MBRP-W is the need for self-initiated stress management skills in women with SUDs during the early stressful periods of residential treatment that increase risk of dropout and relapse.

Detailed description

* This randomized clinical trial will deliver two interventions as add-ons to residential substance use disorder (SUD) treatment: (1) Moment-by-Moment in women's Recovery: Mindfulness-Based Approach to Relapse Prevention (MBRP-W) and (2) Brain and Recovery (B&R) which serves as an active psychoeducational attention control group. * Participants (N=165) who meet study eligibility criteria based on intake assessment will be recruited and complete baseline assessments during weeks 3-6 after entry into a residential treatment program. Participants will be randomly assigned to interventions using Urn randomization. All participants (MBRP-W and B&R) will receive SUD treatment as normally provided by the treatment program. Fifteen participants from each intervention group (N=30) will be selected to participate in a brain imaging (MRI and fMRI) substudy. * Participants will be adult females who have been admitted to a residential treatment center in an urban area of California and who are diagnosed with a SUD based on clinical intake Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) diagnostic assessment. * MBRP-W is delivered in 12 bi-weekly 80-minute group sessions with SUD clinical populations. Facilitators will have previous experience in MBSR facilitation and will be trained in MBRP-W. Each session has a central theme and is divided into five segments consisting of (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and practice assignments for the next class. * B&R is delivered in 12 bi-weekly 80-minute group sessions with SUD clinical populations. Facilitators will be trained in B&R. The B&R group will receive didactic education on the neurobiology of addiction. B&R contains no information on behavior change, relapse prevention, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to that of the current study (i.e., racially/ethnically diverse and low-income women in SUD treatment) with input and review from focus group participants, care providers in SUD treatment, and three experts on the neurobiology of addiction. Topics include: (1) brain structure and function related to addiction, (2) effects of various types of substance use on the brain, and (3) rewarding effects of substance use and how these rewarding effects can lead to addiction. * There are three data collection points, 1) baseline, 2) immediate post-intervention, and 3) 8-months post-intervention completion. Data will be collected in-person by research interviewers via computer-assisted interviews, which includes administration of an alcohol Breathalyzer test to assess alcohol use and collection of a urine sample to assess drug use. Interviews will be conducted at the treatment program (for those who remain in residential treatment) or at convenient locations for participants no longer in treatment. Baseline interview will occur prior to randomization, post-intervention interview will occur within 1-2 weeks of the last group session, and the follow-up interview will occur at an 8-months post-intervention completion window. Brain imaging for a subsample of participants will be completed at baseline and immediate post-intervention. * Number of intervention program class sessions attended will be collected for all enrolled participants. * Participant Satisfaction Surveys measuring acceptability, credibility, and perceived utility of the study arms will be administered to both groups at two class sessions. * Applied Mindfulness Practice Scale (AMPS) measuring the participant's application of mindfulness skills to address life challenges, will be administered to the MBRP-W participants at four class sessions as well as at follow-up. Mindfulness practice effort will also be assessed at these same four class sessions. * An in-treatment clinical record review of services will be collected weekly for the duration of residential treatment.

Interventions

BEHAVIORALMindfulness Meditation

MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.

BEHAVIORALBrain and Recovery (B&R)

B&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B&R group will receive didactic education on the neurobiology of addiction. B&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of Southern California
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

for parent study: * Female * Adult in California (18 years or older) * Diagnosed with a substance use disorder (SUD) * Speaks fluent English * Client at study site, substance use disorder residential facility at time of recruitment

Exclusion criteria

for parent study: * Inability to comprehend informed consent * Unwilling to sign informed consent * Cognitive impairment, psychotic disorder or severe chronic mental health condition based on clinical intake DSM-V assessment * Older than 65 years of age * Reported suicidality in last 30 days * Current prisoner * Pregnant in the 3rd trimester * Pregnant (MRI subsample only) * Not willing to be audio recorded * Not willing to have data stored for research purposes Additional

Design outcomes

Primary

MeasureTime frameDescription
Treatment Completion5 month follow periodNumber of women being designated by the site clinic as a completer during a discharge event.
Days of Any Drug Use8.5 monthsDays of any drug use to include multiple drug types from study intervention end date to follow-up

Secondary

MeasureTime frameDescription
Psychological Symptoms8.5 monthsFive Facet Mindfulness Questionnaire (FFMQ): higher scores indicate better mindfulness qualities (better outcome). Perceived Stress Scale (PSS): higher scores indicate greater perceived stress (worse outcome). Depression Anxiety Stress Scale (DASS): higher scores indicate greater depression, anxiety, and stress (worse outcome). Distress Tolerance Scale (DTS): higher scores indicate greater distress tolerance (better outcome). Difficulties in Emotion Regulation Scale (DERS): higher scores indicate greater difficulties in emotion regulation (worse outcome). Penn Craving Scale (PCS): higher scores indicate greater craving (worse outcome). Positive and Negative Affect Schedule (PANAS) - Negative Affect subscale: higher scores indicate greater negative affect (worse outcome). Minimum and maximum values are not standardized.

Countries

United States

Participant flow

Recruitment details

Participants were adult women clinically diagnosed with SUD and admitted to residential SUD treatment. Recruitment spanned 2015-2018. All patients met one-on-one with the site's intake clinician coordinator. The site psychiatrist and on-site clinician coordinator discussed diagnostic assessment, determined final diagnoses, and made record in the patient chart. The site intake counselor verified study eligibility, and for those women who were eligible, informed clients about our study.

Pre-assignment details

Of 367 potential participants who were screened for the study at the residential site, 200 were eligible and randomized to study conditions and attended the first treatment sessions. Those who missed the first study class session (class overview and introduction) were excluded from the study by design leaving N = 200 enrolled in the trial, 100 per condition.

Participants by arm

ArmCount
Mindfulness Meditation [100 Enrolled]
Mindfulness-Based Relapse Prevention-Women (MBRP-W) Mindfulness Meditation: MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
100
Active Comparator [100 Enrolled]
Brain and Recovery (B&R) Brain and Recovery (B&R): B&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B&R group will receive didactic education on the neurobiology of addiction. B&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
100
Total200

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up137

Baseline characteristics

CharacteristicMindfulness Meditation [100 Enrolled]Active Comparator [100 Enrolled]Total
Age, Continuous32.4 years
STANDARD_DEVIATION 9.8
32.6 years
STANDARD_DEVIATION 8.4
32.5 years
STANDARD_DEVIATION 9.1
Ethnicity (NIH/OMB)
Hispanic or Latino
56 Participants60 Participants116 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
43 Participants38 Participants81 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants2 Participants3 Participants
Region of Enrollment
United States
100 participants100 participants200 participants
Sex: Female, Male
Female
100 Participants100 Participants200 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants
SUD diagnosis DSM5
Alcohol use disorder
10 participants9 participants19 participants
SUD diagnosis DSM5
Both disorders
18 participants14 participants32 participants
SUD diagnosis DSM5
Drug use disorder
71 participants74 participants145 participants
SUD diagnosis DSM5
Missing
1 participants3 participants4 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1000 / 100
other
Total, other adverse events
0 / 1000 / 100
serious
Total, serious adverse events
0 / 1000 / 100

Outcome results

Primary

Days of Any Drug Use

Days of any drug use to include multiple drug types from study intervention end date to follow-up

Time frame: 8.5 months

Population: Women with SUD enrolled in a residential treatment program who remained in the study and completed follow-up assessments approximately 8.5 months after the start of the intervention.

ArmMeasureValue (MEAN)Dispersion
Mindfulness MeditationDays of Any Drug Use16.92 daysStandard Deviation 32.81
Active ComparatorDays of Any Drug Use24.97 daysStandard Deviation 51.65
p-value: <0.05Negative Binomial Hurdle Model
Primary

Treatment Completion

Number of women being designated by the site clinic as a completer during a discharge event.

Time frame: 5 month follow period

Population: Women with SUD at a residential treatment site

ArmMeasureValue (NUMBER)
Mindfulness MeditationTreatment Completion43 Number of women
Active ComparatorTreatment Completion31 Number of women
Comparison: 150 day period was selected for this outcome for a conceptual reason; that being, residential treatment average length of stayp-value: <0.05Regression, Cox
Secondary

Psychological Symptoms

Five Facet Mindfulness Questionnaire (FFMQ): higher scores indicate better mindfulness qualities (better outcome). Perceived Stress Scale (PSS): higher scores indicate greater perceived stress (worse outcome). Depression Anxiety Stress Scale (DASS): higher scores indicate greater depression, anxiety, and stress (worse outcome). Distress Tolerance Scale (DTS): higher scores indicate greater distress tolerance (better outcome). Difficulties in Emotion Regulation Scale (DERS): higher scores indicate greater difficulties in emotion regulation (worse outcome). Penn Craving Scale (PCS): higher scores indicate greater craving (worse outcome). Positive and Negative Affect Schedule (PANAS) - Negative Affect subscale: higher scores indicate greater negative affect (worse outcome). Minimum and maximum values are not standardized.

Time frame: 8.5 months

Population: Women with SUD

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness MeditationPsychological SymptomsDepression Anxiety Stress Scale (high worse; range 0-63)9 score on a non-standardized scaleStandard Deviation 0.6
Mindfulness MeditationPsychological SymptomsDifficulties in emotion regulation scale (high worse, range 7-126)74 score on a non-standardized scaleStandard Deviation 2.4
Mindfulness MeditationPsychological SymptomsPerceived Stress Scale (high worse; range 0-40)18 score on a non-standardized scaleStandard Deviation 0.7
Mindfulness MeditationPsychological SymptomsPenn Alcohol Craving Scale (high worse, range 1-7)1.6 score on a non-standardized scaleStandard Deviation 0.2
Mindfulness MeditationPsychological SymptomsDistress Tolerance Scale (high better; range 1-5)3.3 score on a non-standardized scaleStandard Deviation 0.1
Mindfulness MeditationPsychological SymptomsNegative Affect Subscale (high worse, range 10-50)23 score on a non-standardized scaleStandard Deviation 0.8
Mindfulness MeditationPsychological SymptomsFive Facet Mindfulness Questionnaire (high better; range 5-195)83 score on a non-standardized scaleStandard Deviation 1.3
Active ComparatorPsychological SymptomsNegative Affect Subscale (high worse, range 10-50)23 score on a non-standardized scaleStandard Deviation 0.8
Active ComparatorPsychological SymptomsFive Facet Mindfulness Questionnaire (high better; range 5-195)85 score on a non-standardized scaleStandard Deviation 1.2
Active ComparatorPsychological SymptomsPerceived Stress Scale (high worse; range 0-40)17 score on a non-standardized scaleStandard Deviation 0.06
Active ComparatorPsychological SymptomsDepression Anxiety Stress Scale (high worse; range 0-63)9 score on a non-standardized scaleStandard Deviation 0.6
Active ComparatorPsychological SymptomsDistress Tolerance Scale (high better; range 1-5)3.2 score on a non-standardized scaleStandard Deviation 0.1
Active ComparatorPsychological SymptomsDifficulties in emotion regulation scale (high worse, range 7-126)74 score on a non-standardized scaleStandard Deviation 2.4
Active ComparatorPsychological SymptomsPenn Alcohol Craving Scale (high worse, range 1-7)1.4 score on a non-standardized scaleStandard Deviation 0.2
p-value: <0.05Regression, Linear

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026